Literature DB >> 8883438

Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients.

E T Koh1, P Lee, D D Gladman, M Abu-Shakra.   

Abstract

A retrospective chart review was carried out on 344 patients with systemic sclerosis (SSc) followed prospectively for the occurrence of pulmonary hypertension (PHT). Seventeen patients (4.9%) were found to have PHT. Eight patients had isolated PHT, while in nine PHT was associated with restrictive lung disease (RLD). The subset with RLD developed PHT earlier, but had longer survival than patients with isolated PHT. Patients with limited scleroderma tend to develop isolated PHT, while in those with diffuse disease PHT is associated with RLD. Irrespective of disease type, PHT in SSc has an extremely poor prognosis with a median survival of 12 months following diagnosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8883438     DOI: 10.1093/rheumatology/35.10.989

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  55 in total

1.  Endothelin-I receptor antagonist for the treatment of pulmonary arterial hypertension in systemic sclerosis.

Authors:  John Varga
Journal:  Curr Rheumatol Rep       Date:  2003-04       Impact factor: 4.592

Review 2.  A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism.

Authors:  E Hachulla; J G Coghlan
Journal:  Ann Rheum Dis       Date:  2004-09       Impact factor: 19.103

Review 3.  Lung involvement in systemic sclerosis.

Authors:  Paul M Hassoun
Journal:  Presse Med       Date:  2010-12-30       Impact factor: 1.228

4.  Exercise-induced pulmonary hypertension associated with systemic sclerosis: four distinct entities.

Authors:  Rajeev Saggar; Dinesh Khanna; Daniel E Furst; Shelley Shapiro; Paul Maranian; John A Belperio; Neeraj Chauhan; Philip Clements; Alan Gorn; S Sam Weigt; David Ross; Joseph P Lynch; Rajan Saggar
Journal:  Arthritis Rheum       Date:  2010-12

5.  Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype.

Authors:  Lorinda Chung; Juliana Liu; Lori Parsons; Paul M Hassoun; Michael McGoon; David B Badesch; Dave P Miller; Mark R Nicolls; Roham T Zamanian
Journal:  Chest       Date:  2010-05-27       Impact factor: 9.410

6.  Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing.

Authors:  John H Wlodarczyk; Leslie G Cleland; Anne M Keogh; Keith D McNeil; Kate Perl; Robert G Weintraub; Trevor J Williams
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

7.  Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension.

Authors:  Aránzazu Campo; Stephen C Mathai; Jérôme Le Pavec; Ari L Zaiman; Laura K Hummers; Danielle Boyce; Traci Housten; Hunter C Champion; Noah Lechtzin; Fredrick M Wigley; Reda E Girgis; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2010-03-25       Impact factor: 21.405

8.  Successful treatment with sildenafil in systemic sclerosis patients with isolated pulmonary arterial hypertension: two case reports.

Authors:  Ikuko Hayakawa; Fumiaki Shirasaki; Takashi Hirano; Naoto Oishi; Minoru Hasegawa; Shinichi Sato; Kazuhiko Takehara
Journal:  Rheumatol Int       Date:  2005-05-25       Impact factor: 2.631

Review 9.  [Pulmonary arterial hypertension in collagenoses: clinical features, epidemiology, pathogenesis, diagnosis and treatment].

Authors:  K Ahmadi-Simab; W L Gross
Journal:  Z Rheumatol       Date:  2006-07       Impact factor: 1.372

10.  Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease.

Authors:  Reda E Girgis; Adaani E Frost; Nicholas S Hill; Evelyn M Horn; David Langleben; Vallerie V McLaughlin; Ronald J Oudiz; Ivan M Robbins; James R Seibold; Shelley Shapiro; Victor F Tapson; Robyn J Barst
Journal:  Ann Rheum Dis       Date:  2007-05-01       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.